All In Biotech

Drug Trial Radar · NCT03976323

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC)

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,003 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,003

Actual

Start

Jun 28, 2019

Primary completion

Feb 7, 2024

Study completion Jan 30, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent clinical review (BICR) and 2. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to overall survival (OS).

Conditions

  • Carcinoma, Nonsquamous Non-small-cell Lung

Interventions

  • PembrolizumabBiological

    IV infusion

  • PemetrexedDrug

    IV infusion

  • CarboplatinDrug

    IV infusion

  • CisplatinDrug

    IV infusion

  • OlaparibDrug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Up to ~31 months
  2. Overall Survival (OS)Time frame: Up to ~51 months

Locations

178 sites in 20 countries. Site status is shown where the registry gives one.

  • Alabama Oncology Bruno Cancer Center ( Site 0001)

    Birmingham, Alabama

  • Northwest Alabama Cancer Center, PC ( Site 0002)

    Muscle Shoals, Alabama

  • Disney Family Cancer Center ( Site 0005)

    Burbank, California

  • Boca Raton Regional Hospital ( Site 0018)

    Boca Raton, Florida

  • Mid-Florida Cancer Centers ( Site 0022)

    Orange City, Florida

  • Moffitt Cancer Center ( Site 0024)

    Tampa, Florida

  • Columbus Regional Research Institute ( Site 0098)

    Columbus, Georgia

  • Mount Sinai Hospital Medical Center ( Site 0032)

    Chicago, Illinois

  • Oncology of Northshore ( Site 0033)

    Rolling Meadows, Illinois

  • Methodists Hospitals/Premier Oncology Hematology Associates ( Site 0036)

    Merrillville, Indiana

  • Medstar Good Samaritan Hospital ( Site 0040)

    Baltimore, Maryland

  • Barbara Ann Karmanos Cancer Institute ( Site 0041)

    Detroit, Michigan

  • Hattiesburg Clinic ( Site 0045)

    Hattiesburg, Mississippi

  • Frontier Oncology ( Site 0080)

    Billings, Montana

  • Bozeman Health Deaconness Cancer Center ( Site 0046)

    Bozeman, Montana

  • Waverly Hematology Oncology ( Site 0081)

    Cary, North Carolina

  • Thompson Cancer Survival Center ( Site 2812)

    Knoxville, Tennessee

  • University of Tennessee Medical Center Knoxville ( Site 0060)

    Knoxville, Tennessee

  • Renovatio Clinical ( Site 0062)

    The Woodlands, Texas

  • Cancer Care Northwest ( Site 0071)

    Spokane Valley, Washington

  • Clínica Universitaria Reina Fabiola ( Site 0505)

    Córdoba, Argentina

  • Sanatorio Privado San Geronimo S.R.L ( Site 0510)

    Santa Fe, Argentina

  • Hospital Italiano Regional del Sur ( Site 0509)

    Bahía Blanca, Buenos Aires, Argentina

  • Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0511)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Hospital Britanico de Buenos Aires ( Site 0500)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Instituto Medico Rio Cuarto ( Site 0501)

    Río Cuarto, Córdoba Province, Argentina

  • Centro Oncológico de Rosario ( Site 0507)

    Rosario, Santa Fe Province, Argentina

  • Centro Medico San Roque ( Site 0506)

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Liverpool Hospital ( Site 1201)

    Liverpool, New South Wales, Australia

  • Southern Medical Day Care Centre ( Site 1200)

    Wollongong, New South Wales, Australia

  • Townsville General Hospital ( Site 1202)

    Townsville, Queensland, Australia

  • Monash Cancer Centre ( Site 1205)

    Clayton, Victoria, Australia

  • Krankenhaus Nord - Klinik Floridsdorf ( Site 1300)

    Vienna, Austria

  • Social Medical Center - Otto Wagner Hospital ( Site 1301)

    Vienna, State of Vienna, Austria

  • Innsbruck LKH ( Site 1302)

    Innsbruck, Tyrol, Austria

  • Ordensklinikum Linz GmbH Elisabethinen ( Site 1307)

    Linz, Upper Austria, Austria

  • Klinikum Wels-Grieskirchen ( Site 1304)

    Wels, Upper Austria, Austria

  • Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0203)

    Rio de Janeiro, Brazil

  • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0200)

    São Paulo, Brazil

  • BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0214)

    São Paulo, Brazil

Showing 40 of 178 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.